

## Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: minimal size of the groups n = 5

## EQA round: BM2/22 - Bone Markers

Deadline: 28.10.2022

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]						Comparability								
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	
<b>(431) Parathyrintact (PTH)</b>					87							84	81	96%	
Samples and groups	[pmol/L]														
<b>Sample A</b>		8,15	3,0	37	87							84	82	98%	
(1) Abbott		13,3	1,2	8,7	18	0	CVPG	13,3	0,67	23%	10,2	16,4	18		
(12) Beckman Coulter		4,70	0,089	1,9	9	0	CVPG	4,7	0,11	23%	3,61	5,79	9		
(60) Roche		6,89	0,64	9,3	39	0	CVPG	6,89	0,25	23%	5,3	8,48	39		
(162) Siemens (Atellica)		7,90	0,44	5,6	8	0	CVPG	7,9	0,34	23%	6,08	9,72	8		
(179) Siemens		8,22	0,44	5,3	10	0	CVPG	8,22	0,34	23%	6,32	10,2	10		
Other					3	1							0		
								1x 25, 2x 29							
<b>Sample B</b>		23,1	7,8	34	87							84	81	96%	
(1) Abbott		37,3	3,4	9,0	18	0	CVPG	37,3	1,9	23%	28,7	45,9	18		
(12) Beckman Coulter		14,9	0,62	4,1	9	0	CVPG	14,9	0,76	23%	11,4	18,4	9		
(60) Roche		20,0	2,0	9,9	39	0	CVPG	20,0	0,78	23%	15,4	24,6	39		
(162) Siemens (Atellica)		24,0	1,9	8,0	8	0	CVPG	24,0	1,5	23%	18,4	29,6	8		
(179) Siemens		25,0	1,2	4,8	10	0	CVPG	25,0	0,92	23%	19,2	30,8	10		
Other					3	0							0		
								1x 25, 2x 29							
<b>(436) Parathyrintact (PTH 1-84)</b>					50							49	48	98%	
Samples and groups	[pmol/L]														
<b>Sample A</b>		4,29	0,41	9,5	50							49	48	98%	
(60) Roche		4,39	0,23	5,3	41	0	CVPG	4,39	0,089	17%	3,64	5,14	41		
(164) DiaSorin		3,30	0,30	9,0	8	0	CVPG	3,3	0,23	17%	2,73	3,87	8		
Other					1	0							0		
								1x 73							
<b>Sample B</b>		13,3	0,92	6,9	50							49	48	98%	
(60) Roche		13,5	0,72	5,4	41	0	CVPG	13,5	0,28	17%	11,2	15,8	41		
(164) DiaSorin		12,0	1,9	16	8	0	CVPG	12,0	1,5	17%	9,96	14,1	8		
Other					1	0							0		
								1x 73							
<b>(432) Collagen telopeptide CTx-beta</b>					94							94	87	93%	
Samples and groups	[ng/L]														
<b>Sample A</b>		296	24	8,0	94							94	91	97%	
(60) Roche		299	21	7,0	88	0	CVPG	299	5,4	17%	248	350	88		
(73) Snibe		104	7,8	7,5	6	0	CVPG	104	11	17%	86,3	122	6		
Other		704	61	8,7	94								94	88	94%
<b>Sample B</b>		711	54	7,6	88	1	CVPG	711	14	17%	590	832	88		
(60) Roche		711	54	7,6	88	1	CVPG	711	14	17%	590	832	88		
(73) Snibe		266	42	16	6	0	CVPG	266	59	17%	220	312	6		
Other					1	0							0		
								1x 183							
<b>(433) P1NP</b>					74							73	68	93%	
Samples and groups	[µg/L]														
<b>Sample A</b>		33,9	3,4	10	74							73	68	93%	
(60) Roche		33,4	2,8	8,5	67	1	CVPG	33,4	0,85	20%	26,7	40,1	67		
(73) Snibe		55,3	9,3	17	6	0	CVPG	55,3	13	20%	44,2	66,4	6		
Other					1	1							0		
								1x 183							
<b>Sample B</b>		213	20	9,2	74							73	70	96%	
(60) Roche		213	19	9,0	67	0	CVPG	213	5,7	20%	170	256	67		
(73) Snibe		227	15	6,5	6	0	CVPG	227	21	20%	181	273	6		
Other					1	0							0		
								1x 183							
<b>(434) Osteocalcin</b>					79							72	68	94%	
Samples and groups	[µg/L]														
<b>Sample A</b>		18,4	1,2	6,8	79							72	69	96%	
(60) Roche		18,5	1,1	5,8	72	0	CVPG	18,5	0,31	13%	16	21	72		
Other					7	0							0		
								2x 29, 1x 73, 4x 164							
<b>Sample B</b>		90,2	7,3	8,1	79							72	69	96%	
(60) Roche		91,1	6,3	6,9	72	0	CVPG	91,1	1,8	13%	79,2	103	72		
Other					7	0							0		
								2x 29, 1x 73, 4x 164							
<b>(435) 25-hydroxyvitamin D</b>					167							157	147	94%	
Samples and groups	[nmol/L]														
<b>Sample A</b>		66,8	14	21	167							157	149	95%	
(1) Abbott		55,8	3,3	5,9	43	0	CVPG	55,8	1,2	33%	37,3	74,3	43		
(12) Beckman Coulter		165	14	8,4	14	0	CVPG	165	9,0	33%	110	220	14		
(60) Roche		71,4	11	16	62	0	CVPG	71,4	3,5	33%	47,8	95	62		

## Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: minimal size of the groups n = 5

## EQA round: BM2/22 - Bone Markers

Deadline: 28.10.2022

Test	[unit]					Comparability							N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL				
<b>(435) 25-hydroxyvitamin D</b>					167								157	147	94%
Samples and groups	[nmol/L]														
<b>Sample A</b>		66,8	14	21	167								157	149	95%
(162) Siemens (Atellica)		65,2	7,4	11	14	0	CVPG	65,2	4,8	33%	43,6	86,8	14		
(164) DiaSorin		67,5	6,4	9,5	14	0	CVPG	67,5	4,2	33%	45,2	89,8	14		
(179) Siemens		63,7	12	19	10	0	CVPG	63,7	9,6	33%	42,6	84,8	10		
Other					10	0							0		
								1x 5, 1x 15, 1x 25, 4x 256, 1x 998, 2x 999							
<b>Sample B</b>		147	22	15	167								157	151	96%
(1) Abbott		134	7,6	5,7	43	0	CVPG	134	2,8	33%	89,7	179	43		
(12) Beckman Coulter		274	21	7,5	14	0	CVPG	274	14	33%	183	365	14		
(60) Roche		156	18	11	62	0	CVPG	156	5,6	33%	104	208	62		
(162) Siemens (Atellica)		144	12	8,3	14	0	CVPG	144	7,8	33%	96,4	192	14		
(164) DiaSorin		137	11	8,2	14	0	CVPG	137	7,3	33%	91,7	183	14		
(179) Siemens		144	15	10	10	0	CVPG	144	12	33%	96,4	192	10		
Other					10	0							0		
								1x 5, 1x 15, 1x 25, 4x 256, 1x 998, 2x 999							

st\_kn\_p

End of report

Printed: 07.11.2022